Skip to main content

Table 4 Safety of maintenance-Bevacizumab (total patients n= 35)

From: Maintenance bevacizumab beyond first-line paclitaxel plus bevacizumab in patients with Her2-negative hormone receptor-positive metastatic breast cancer: efficacy in combination with hormonal therapy

Toxicity Grade 1 Grade 2 Grade 3 Grade 4
n(%) n(%) n(%) n(%)
Bleeding 2 (5.7)   - -
Protenuria - 3 (8.5) 4 (11.4) -
Hypertension 1 (2.8) 2 (5.7) 3 (8.5) -
Neurotoxicity 1 (2.8) - - -
LVS disfunction 1 (2.8) - - -
Other events    Pneumonia 1 (2.8)